Amphastar Pharmaceuticals (AMPH) EBIT (2013 - 2026)

Amphastar Pharmaceuticals' EBIT history runs 14 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• On a quarterly basis, EBIT fell 63.45% year-over-year to $13.6 million in Q1 2026; TTM through Mar 2026 was $116.7 million, a 40.04% decrease from a year earlier, with the FY2025 full-year figure at $140.4 million, down 31.65% from the prior year.
• EBIT retreated to $13.6 million in Q1 2026 per AMPH's latest filing, from $35.6 million in the prior quarter.
• Across five years, EBIT topped out at $72.7 million in Q3 2023 and bottomed at $13.6 million in Q1 2026.
• The 5-year median for EBIT is $37.3 million (2025), against an average of $39.1 million.
• Across the five-year window, EBIT surged 212.89% in 2023 and sank 63.45% in 2026, its largest moves.
• Year by year, EBIT stood at $37.8 million in 2022, then jumped by 42.68% to $54.0 million in 2023, then retreated by 16.37% to $45.1 million in 2024, then retreated by 21.13% to $35.6 million in 2025, then sank by 61.72% to $13.6 million in 2026.
• Per Business Quant, the three latest AMPH EBIT figures stand at $13.6 million (Q1 2026), $35.6 million (Q4 2025), and $25.3 million (Q3 2025).